Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New research at the Oxford Martin School aims to unlock power of big data and open innovation for medicine

Innovation Research

The Oxford Martin School is funding two new research programmes that will harness the power of data and collaboration to advance the field of medicine.

The longevity we enjoy today has brought new problems: a rise in chronic conditions such as diabetes, dementia and heart failure, made more complicated by many patients suffering from multiple conditions. At the same time, while the need for new medicines continues to grow unabated, our costly and inefficient drug discovery systems see less than one per cent of efforts reach the market.

These two new research programmes – the Oxford Martin Programme on Deep Medicine and the Oxford Martin Programme on Affordable Medicine – take radical new approaches to these major global challenges.

Read more (Oxford Martin School website)

Similar stories

Children and Adolescents’ Mental Health: One Year On

Coronavirus COVID-19 General Research

Parents and carers reported that behavioural, emotional and attentional difficulties in their children changed considerably throughout the past year, increasing in times of national lockdown and decreasing as restrictions eased and schools reopened, according to the latest Co-SPACE (COVID-19 Supporting Parents, Adolescents, and Children in Epidemics) study, led by experts at the University of Oxford.

Promising malaria vaccine enters final stage of clinical testing in West Africa

Clinical Trials General Research

First vaccinations have now begun in Mali in a phase III trial of a malaria vaccine developed at the University of Oxford. Known as R21/Matrix-M, it recently showed efficacy of 77% over 12 months in a phase IIb trial, and it is hoped that this phase III trial will help to lead to licensure of this malaria vaccine by 2023.

Multi-partner 'OpenMind' consortium to develop technology for new generation of neurostimulation devices

General Research

Investigators at the University of Oxford, University of California San Francisco (UCSF), Brown University and the Mayo Clinic have joined forces to develop open-source technology platforms for a new generation of neurostimulation devices that not only provide stimulation to the brain but also sense, record, and stream brain activity.

Why we must expand newborn screening

General Research

Professor Laurent Servais of the Department of Paeditrics writes for the Oxford Science Blog on why it is important that we become much more efficient in the diagnosis of treatable conditions and in the treatment of these diseases.

Severe COVID in young people can mostly be explained by obesity – new study

General Research

Oxford vaccine professor: rich countries have a moral duty to share their COVID-19 shots

Coronavirus COVID-19 General Research